Summary & Overview
HCPCS S2341: Chemodenervation of Vocal Cord Adductor Muscles
HCPCS Level II code S2341 designates chemodenervation of the vocal cord adductor muscles, a targeted laryngologic injection procedure commonly performed to treat conditions such as focal laryngeal dystonia and spastic dysphonia. Nationally, this code identifies a specialized outpatient therapeutic intervention with implications for clinical access, coding consistency, and reimbursement for voice-related functional improvement.
Key payers included in the national view are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical settings where the service is delivered, and which major payers are included in payer comparisons. The publication summarizes common modifiers and practical billing context; where specific payer coverage rules, rates, or clinician taxonomies are not provided, it notes that Data not available in the input.
This report provides clinical context for coders and policy analysts, outlines expected service lines and sites of care, and identifies areas where policy variations commonly arise, including prior authorization practices and settings of service. The content is intended to support administrative clarity, coding accuracy, and informed discussion of coverage considerations at a national level.
Billing Code Overview
HCPCS Level II code S2341 describes chemodenervation of adductor muscle(s) of the vocal cord. This procedure involves injection(s) of a neurolytic or neuromodulating agent into the adductor muscles of the vocal fold(s) to reduce unwanted muscle contraction and improve glottic function.
Service Type: Therapeutic chemodenervation (laryngeal botulinum toxin injection)
Typical Site of Service: Ambulatory surgical center or hospital outpatient setting; may also be performed in-office with appropriate laryngologic equipment and monitoring
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with adductor-type spasmodic dysphonia presenting with strained, strangled voice and voice breaks. The patient is evaluated in an otolaryngology or laryngology clinic, including history, perceptual voice assessment, and flexible laryngoscopy to confirm excessive vocal fold adduction during phonation. After discussion of risks, benefits, and alternatives, the patient returns for office-based chemodenervation of the thyroarytenoid (adductor) muscle(s) using botulinum toxin injected via transcutaneous or percutaneous approach with electromyographic (EMG) or endoscopic guidance.
Preprocedure workflow includes informed consent, medication review, and topical or local anesthesia as needed. The procedure is performed in an outpatient clinic, procedure room, or ambulatory surgical center. Postprocedure monitoring focuses on immediate airway and swallowing status; patients are given postprocedure voice and swallowing precautions and scheduled follow-up for voice outcome assessment and potential repeat injections at therapeutic intervals (commonly 3–6 months). Documentation includes indication, laterality, agent and units, injection technique (EMG or endoscopic guidance), complications, and instructions for follow-up.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when only the physician professional component is billed separate from a facility or technical component for guidance or interpretation during the procedure. |